Trials / Completed
CompletedNCT01541618
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
A Longitudinal Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 15 (actual)
- Sponsor
- MSDx, Inc. · Industry
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare biomarker levels in Multiple Sclerosis (MS) patients before and after beginning Natalizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | MSDX Complex-1 Biomarker test | MSDX Complex-1 Biomarker test |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2012-03-01
- Last updated
- 2020-09-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01541618. Inclusion in this directory is not an endorsement.